2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.07 Ricciuti

PP01.07 Ricciuti - Poster

Pdf Summary

The document discusses the genomic landscapes and characteristics of mutant RAS in human cancers, specifically focusing on the management of KRAS G12C-mutated advanced non-small-cell lung cancer. The study aims to analyze the clinical, pathologic, and genomic features of KRAS amplification in non-small cell lung cancer using a large cohort of 15,000 patient samples. Data from various cancer studies were evaluated to understand the implications of KRAS amplification in patient outcomes.<br /><br />The research reveals that KRAS amplification defines a unique subset of non-small cell lung cancers with distinct features and poorer survival rates. The study emphasizes the need for developing novel therapeutic strategies to target KRAS amplification for improved outcomes in patients with non-small cell lung cancer. Various patient characteristics such as age, sex, smoking history, and histology were also analyzed in relation to KRAS amplification.<br /><br />Additionally, the genomic profile of KRAS-amplified non-small cell lung cancers was examined to identify the top 20 mutated genes in these cases. The findings suggest that KRAS amplification plays a significant role in the development and progression of non-small cell lung cancer, highlighting the importance of further research and targeted therapies in this specific subset of patients. The study provides valuable insights into the potential for personalized treatment approaches for patients with KRAS-amplified non-small cell lung cancer.

Keywords

genomic landscapes

mutant RAS

KRAS G12C-mutated

non-small-cell lung cancer

KRAS amplification

patient samples

therapeutic strategies

genomic profile

mutated genes

personalized treatment approaches